Study of MAR002 in Healthy Men

Part of paid clinical trials in Tempe, Arizona.

Sponsor
Marea Therapeutics
Study ID
NCT07195175
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Acromegaly

Eligibility Criteria

Sex
MALE
Age
18 Years - 40 Years
Healthy Volunteers
Accepted

Interventions

  • MAR002 — DRUG
    subcutaneous injection
  • Placebo — DRUG
    Subcutaneous injection

Study Details

Evaluate the safety and tolerability of subcutaneous (SC) administration of MAR002 in healthy men

Key Dates

Start date
Aug 11, 2025
Status verified
Jan 2026
Primary completion
Jul 31, 2026
Completion
Jul 31, 2026

Study Design

Enrollment
45 participants (estimated)
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Dose A MAR002
    Subcutaneous injection
  • Experimental: Dose B MAR002
    Cohort 2 receiving single Dose B
  • Experimental: Dose C MAR002
    Cohort 3 receiving single Dose C
  • Experimental: Dose D MAR002
    Cohort 4 receiving single Dose D
  • Experimental: Dose E MAR002
    Cohort 5 receiving single Dose E
  • Experimental: Dose F MAR002
    Cohort 6 receiving multiple Dose F

Primary Outcome Measure

Number of participants with TEAEs (treatment-emergent adverse events) [ Time Frame: From first dose of study drug through final End of Study/Early Termination Visit. End of Study is Day 64 for Cohorts 1 and 2; End of Study is day 169 for Cohorts 3, 4, 5, and 6. ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Marea SiteTempeArizona85283-

Find similar trials in Tempe, AZ

By research site
Marea Site· Tempe, AZ

Related Studies